Drug intelligence / Profile preview

D935

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

D935 is a reference drug that has been utilized in randomized, open-label, single-dose, crossover pharmacokinetic and safety studies involving healthy volunteers. These studies, sponsored by Chong Kun Dang Pharmaceutical, aim to compare D935 (administered orally as a capsule or tablet) with CKD-385, a test drug. The administration of D935 has been evaluated under both fasted and fed conditions. The specific canonical name, mechanism of action, and primary indication of D935 are not disclosed in the provided context.

Other names: D935 Cap.D-935 Cap.D 935 Cap.

Beyond the preview

Go deeper on D935.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D935.

Explore the full profile